SNP recommendation guidelines: Difference between revisions

Safer nicotine wiki Tobacco Harm Reduction
Jump to navigation Jump to search
m (NZ summary (also limited counter indicators))
(add TGA summary)
Line 41: Line 41:
* Devices regulated according to EU TDP, notified to MHRA, covered under GPSR.
* Devices regulated according to EU TDP, notified to MHRA, covered under GPSR.
* Not currently licensed as medicines.
* Not currently licensed as medicines.
* People who smoke but can't/won't quit. can reduce harm by smoking less or substituting temporarily. Harm reduction benefits are uncertain, but may inspire full quitting.
* People who smoke but can't/won't quit. can reduce harm by smoking less or substituting temporarily.
* Harm reduction benefits are uncertain, but may inspire full quitting.
|-
|See also
|[https://www.gov.uk/government/publications/nicotine-vaping-in-england-2022-evidence-update Nicotine vaping in England: 2022 evidence update]
|}
|}


Line 114: Line 118:
* Vaping is almost twice as effective as NRTs.
* Vaping is almost twice as effective as NRTs.
* Goal: reducing the strength of your nicotine.
* Goal: reducing the strength of your nicotine.
|}
== Australia ==
=== Nicotine vaping products: Information for prescribers ===
{| class="wikitable"
|+
!
!
|-
|Link
|https://www.tga.gov.au/resources/resource/guidance/nicotine-vaping-products-information-prescribers
|-
|Audience
|GPs / PWS
|-
|By
|Therapeutic Goods Administration
|-
|Considerations
|
* NVPs are Schedule 4 (prescription only) medicines, but remain 'unapproved'.
* Their potential efficacy for smoking cessation is currently mixed.
* [https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/supporting-smoking-cessation/tobacco-harm-reduction RACGP guideliness] apply, and NVPs are '''not first line treatment''' for smoking cessation.
* Availability hinges on authorised prescriber, special access, or personal importation scheme.
* TGA has a [https://www.tga.gov.au/resources/resource/guidance/authorised-prescribers-unapproved-nicotine-vaping-products list of authorised prescribers] (GPs).
|}
|}

Revision as of 15:42, 12 October 2022

Some countries and medical organizations have provided recommendations on which tobacco treatment cases might benefit from safer nicotine products as cessation option.

Canada

Lower-Risk Nicotine Use Guidelines (LRNUG)

Link https://www.nicotinedependenceclinic.com/en/lower-risk-nicotine-user-guidelin-es
Audience GPs
By CAMH, Pharmacists for a Smoke-Free Canada (NGO)
Considerations
  • E-cigarettes combined with behavioural are a suitable cessation aid.
  • Complete switch should be advised.
  • No specific device type recommended.
  • Advise that there's no long-term risk quantification yet.
  • Continued use reduces relapse risk.

UK

NICE guidelines (NG209)

Link https://www.nice.org.uk/guidance/ng209
Audience GPs
By Gov UK / OHID
Considerations
  • E-cigarettes are applicable for nicotine substitution.
  • Devices regulated according to EU TDP, notified to MHRA, covered under GPSR.
  • Not currently licensed as medicines.
  • People who smoke but can't/won't quit. can reduce harm by smoking less or substituting temporarily.
  • Harm reduction benefits are uncertain, but may inspire full quitting.
See also Nicotine vaping in England: 2022 evidence update

Using e-cigarettes to stop smoking

Link https://www.nhs.uk/live-well/quit-smoking/using-e-cigarettes-to-stop-smoking/
Audience PWS
By National Health Service
Considerations
  • Growing evidence e-cigarettes can be effective.
  • Using it as much as you need to and with the right strength of nicotine in your e-liquid.
  • Full benefit from vaping requires to stop smoking cigarettes completely.
  • Expert help from local stop smoking service advised.
  • While nicotine is the addictive substance in cigarettes, it's relatively harmless.
  • For pregnancy, licensed NRT is advised, e-cigs only as fallback option.

New Zealand

Vaping products: Information for health care workers and stop-smoking services

Link https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/tobacco-control-information-practitioners/vaping-products-information-health-care-workers-and-stop-smoking-services
Link https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/vaping-smokefree-environments-and-regulated-products/position-statement-vaping
Audience GPs
By NZ Ministry of Health
Considerations
  • Ministry of Health encourages smokers who want to use vaping products to quit smoking to seek the support of local stop smoking services.
  • Vaping products are a less harmful way of delivering nicotine than conventional tobacco cigarettes.
  • Expert opinion is that vaping products are much less harmful than smoking tobacco but not completely harmless.
  • Toxicants have been found in vapor, but in general, at levels much lower than found in cigarette smoke or at levels that are unlikely to cause harm.
  • When used as intended, vaping products pose no risk of nicotine poisoning to users. Short-term risks appear to no different than NRT, long-term quantification still unknown.
  • Combining vaping with behavioural support is likely to have comparable success rate to stop-smoking medication.
  • Stop smoking services should be ‘vaping friendly’, provide accurate information about benefits and risks, and advice about obtaining a suitable vaping product.
  • Anyone who is switching from smoking to vaping should stop smoking tobacco as soon as possible.
  • There is no international evidence that vaping products are undermining the long-term decline in cigarette smoking among adults and youth, and may in fact be contributing to it.

VapingFacts

Link https://vapingfacts.health.nz/vaping-to-quit-smoking/
Audience PWS
By NZ Ministry of Health
Considerations
  • No device approved as an official stop-smoking medicine.
  • Has helped many people quit smoking.
  • Addresses the sensory, behavioural and social aspects.
  • NRT and medical options still exist.
  • Vaping is almost twice as effective as NRTs.
  • Goal: reducing the strength of your nicotine.

Australia

Nicotine vaping products: Information for prescribers

Link https://www.tga.gov.au/resources/resource/guidance/nicotine-vaping-products-information-prescribers
Audience GPs / PWS
By Therapeutic Goods Administration
Considerations
  • NVPs are Schedule 4 (prescription only) medicines, but remain 'unapproved'.
  • Their potential efficacy for smoking cessation is currently mixed.
  • RACGP guideliness apply, and NVPs are not first line treatment for smoking cessation.
  • Availability hinges on authorised prescriber, special access, or personal importation scheme.
  • TGA has a list of authorised prescribers (GPs).